KILITCH DRUGS (INDIA) LTD. - 524500 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed the copies of the newspaper publication pertaining to the extract of the financial results of the Company for the quarter and year ended 31st March, 2022. The said extract of the financial results was published in on Marathi and English edition on 28th May, 2022. KILITCH DRUGS (INDIA) LTD. - 524500 - Appointment of Company Secretary and Compliance Officer
Appointment of Ms. Pushpa Nyoupane as Company Secretary of the Company with effect from 5th May, 2022 KILITCH DRUGS (INDIA) LTD. - 524500 - Financial Results For The Quarter And Year Ended 31.03.2022
Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,we hereby would like to inform you that Board of Directors of the Company, at its meeting held today i.e.26th May, 2022, have considered and approved the following; 1.Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2022. The copy of Audited Financial Results (Standalone and Consolidated) as adopted and approved by the Board of Directors and Auditor''s report thereon are attached herewith for your ready reference. 2.Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company have issued their audit reports with unmodified (i.e., unqualified) opinion on the Financial Statements (Standalone and Consolidated) for the year ended on 31st March, 2022. KILITCH DRUGS (INDIA) LTD. - 524500 - Submission Of Acknowledgement Received From Securities And Exchange Board Of India For The Report Submitted Under Regulation 10(7) Of SEBI(Substantial Acquisition Of Shares And Takeovers) Regulations, 2021
Please find enclosed herewith the acknowledgement received from Securities and Exchange Board of India for the report submitted under regulation 10(7) of SEBI(Substantial Acquisition of Shares and Takeovers) Regulations, 2021 for your record. KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Intimation for Considering The Financial Results For The Quarter And Financial Year Ended 31St March, 2022
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Meeting of the Board of Directors of the Company will be held on Thursday, 26th May, 2022 inter-alia to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March, 2022. Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2nd April, 2019 issued by NSE, the Trading Window has been closed with effect from 1st April, 2022 and will re-open 48 hours after said financial results are disclosed to the Stock Exchanges. KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, please find enclosed herewith Annual Secretarial Compliance Report for the financial year the year ended 31st March, 2022 issued by practicing company secretary, Deep Shukla & Associates. KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhavin Mehta KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosure Under Regulation 7(2) (B) Of SEBI (Prohibition Of Insider Trading) Regulations. 2015.
In terms of Regulation 7(2)(b) of SEBI (Prohibition of Insider Trading) Regulations, 2015, enclosed please find disclosures received from below mentioned insiders in Form C. - Mr. Mukund Mehta for disposal of 11,11,768 equity through interse transfer to Mr. Bhavin Mehta on 22nd April, 2022 - Mr. Bhavin Mehta for acquisition of 11,11,768 equity through interse transfer from Mr. Mukund Mehta on 22nd April, 2022 Copy of disclosures received from the above mentioned insiders who belongs to promoter group in Form ''C'' pursuant to Regulation 7(2)(a) of SEBI (Prohibition of Insider Trading) Regulations, 2015 are enclosed herewith.
